Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma |
| |
Authors: | Cheng-Jui Lin Ken-Hong Lim Yi-Chou Cheng Han-Hsiang Chen Chih-Jen Wu |
| |
Institution: | (1) Division of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, 92 Chung San North Road, Section 2, Taipei, 104, Taiwan;(2) Division of Hematology and Oncology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan;(3) Mackay Medicine, Nursing and Management College, Taipei, Taiwan;(4) Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan |
| |
Abstract: | Tumor lysis syndrome is a set of life threatening complication that can arise from treatment of high tumor burden, drug sensitive,
and rapidly proliferating neoplasm particularly of hematological origin. It is rarely described in patients with solid tumors.
We report the first case of tumor lysis syndrome in a man with metastatic renal pelvic transitional cell carcinoma after gemcitabine
treatment. Despite aggressive therapy, he died 2 weeks after TLS was diagnosed. Our experience demonstrates that administration
of gemcitabine for metastatic renal pelvic transitional cell carcinoma may induce acute tumor lysis syndrome, which necessitates
frequent laboratory monitoring and prompt initiation of appropriate therapeutic measures. |
| |
Keywords: | Tumor lysis syndrome Transitional cell carcinoma Gemcitabine |
本文献已被 PubMed SpringerLink 等数据库收录! |
|